Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPIV3-EbovZ GP vaccine for Ebola
NCT02564575Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2015
- Primary completion
- Nov 2016
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of human parainfluenza virus type 3 Ebola vaccine in Ebola virus disease (EVD) (2 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of vaccine-related reactogenicity events at Day 56, Number of vaccinees infected with HPIV3-EbovZ GP vaccine virus at Day 360 and 2 more. Started Aug 2015; status: completed.
02
Drugs
human parainfluenza virus type 3 Ebola vaccine
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02564575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564575.